DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
Stock Information for DURECT Corporation
Loading
Please wait while we load your information from QuoteMedia.